A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
Public ClinicalTrials.gov record NCT05001347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.
Study identification
- NCT ID
- NCT05001347
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2, 2021 (Actual)
- Primary completion
- Feb 8, 2023 (Actual)
- Completion
- Feb 8, 2023 (Actual)
- Last update posted
- Dec 16, 2025
2021 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Tucson | Arizona | 85711 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| Medical Oncology Hematology Consultants, PA | Newark | Delaware | 19713 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| Women's Cancer Care | Covington | Louisiana | 70433 | — |
| Maryland Oncology Hematology | Rockville | Maryland | 20850 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York | 10016 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| Tri County Hematology and Oncology Associates | Massillon | Ohio | 44646 | — |
| Texas Oncology - Arlington North | Arlington | Texas | 76012 | — |
| Texas Oncology - Austin Central | Austin | Texas | 78731 | — |
| Texas Oncology - Forth Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| Texas Oncology - The Woodlands, Gynecologic Oncology | The Woodlands | Texas | 77380 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Northwest Cancer Specialists | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05001347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2025 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05001347 live on ClinicalTrials.gov.